S100A6 Antibody

What is S100A6 protein and what are its key structural features?

S100A6 (calcyclin) is a 10 kDa calcium-binding protein belonging to the S100 family. Mouse S100A6 is 89 amino acids in length and contains two calcium-binding EF-hand domains located at amino acids 12-47 and 48-83. Intracellularly, S100A6 can form both noncovalent homodimers and heterodimers with S100B and SGT1. It can also be secreted extracellularly through a noncanonical pathway, where it binds to RAGE receptors and can induce apoptosis . The protein is expressed in multiple cell types including neurons, endothelial cells, fibroblasts, and glandular epithelia . Mouse S100A6 shares 99% amino acid identity with rat S100A6 and 96% with human S100A6, making it highly conserved across species .

How is S100A6 involved in cellular functions and disease processes?

S100A6 was first identified as a gene whose expression increases when quiescent cells are stimulated to proliferate . Multiple lines of evidence have confirmed its involvement in cell cycle regulation, with S100A6 gene-deficient cells showing reduced proliferative activities . At the molecular level, S100A6 interacts with multiple target proteins including Siah-1-interacting protein (SIP), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and several annexins . Its expression is elevated in various malignant tumors, including acute myeloid leukemia, neuroblastoma, and melanoma cell lines, suggesting potential value as a diagnostic cancer marker . Interestingly, in prostate tissue, S100A6 shows intense expression in basal cells of benign epithelium but complete loss of expression in all cases of prostatic adenocarcinoma, indicating that loss of S100A6 may be an early event in prostate cancer development .

What are the major applications of S100A6 antibodies in research?

S100A6 antibodies serve multiple research purposes including:

• Immunohistochemical analysis of tissue samples to determine protein localization and expression patterns

• Western blot analysis for protein expression quantification

• Cell type identification in heterogeneous tissue samples

• Diagnostic applications in cancer research, particularly prostate cancer where loss of S100A6 expression may serve as a novel diagnostic marker

• Investigation of calcium signaling pathways and cell cycle regulation

• Studying expression changes during malignant transformation

The antibodies have been validated for use in Western blotting, immunohistochemistry, and confocal microscopy with specific protocols established for each application .

What are the optimal conditions for Western blot detection of S100A6?

For optimal Western blot detection of S100A6, researchers should follow these methodological guidelines:

• Sample preparation: Prepare cell or tissue lysates under reducing conditions using appropriate lysis buffers (e.g., Immunoblot Buffer Group 1 or 8, depending on the sample type) .

• Gel selection: Use 15-20% gradient gels or similar high percentage SDS-PAGE gels appropriate for detecting low molecular weight proteins (~10 kDa) .

• Transfer conditions: Transfer to PVDF membrane (e.g., Immobilon P) using standard transfer conditions optimized for small proteins .

• Antibody dilution: For sheep anti-human/mouse S100A6 polyclonal antibody (R&D Systems), use at 1 μg/mL concentration. For other antibodies, determine optimal concentration through titration .

• Detection system: Use appropriate HRP-conjugated secondary antibodies (e.g., anti-sheep IgG) followed by standard chemiluminescence detection .

S100A6 typically appears as a single band at approximately 10 kDa under reducing conditions, though in some detection systems it may appear at approximately 7 kDa . Specificity can be confirmed using S100A6 knockout cell lines as negative controls, such as the S100A6 knockout HEK293T cell line .

What immunohistochemistry protocols yield optimal results with S100A6 antibodies?

For immunohistochemical detection of S100A6 in tissue sections, the following protocol yields optimal results:

• Tissue preparation: Use paraffin-embedded tissue sections fixed with appropriate fixatives.

• Antigen retrieval: Perform heat-induced epitope retrieval using basic antigen retrieval reagents. For example, treat sections before primary antibody incubation .

• Blocking: Block nonspecific binding using appropriate blocking reagents.

• Primary antibody: For sheep anti-human/mouse S100A6 antibody, use at 3 μg/mL concentration and incubate overnight at 4°C .

• Detection system: Use HRP-DAB cell & tissue staining kits for visualization, followed by hematoxylin counterstaining for nuclei .

• Controls: Include both positive controls (tissues known to express S100A6, such as basal cells in prostate epithelium) and negative controls (S100A6-negative tissues or isotype controls).

For confocal microscopy applications, maintain consistent settings (aperture, detector gain, and offset) throughout experiments to ensure quantitative comparability between samples. Use optical slices of <0.6 μm thickness for optimal resolution .

How can researchers confirm the specificity of S100A6 antibodies?

Confirming antibody specificity is crucial for reliable research results. Several approaches can be employed:

• Recombinant protein testing: Test antibodies against recombinant S100A6 protein and related S100 family members to confirm specificity. Western blot analysis should show reactivity with S100A6 but not with other S100 proteins, even when the latter are present in excess (e.g., 6-fold quantity) .

• Knockout cell lines: Use S100A6 knockout cell lines as negative controls. For example, Western blot analysis of parental HEK293T cells should show S100A6 expression, while S100A6 knockout HEK293T cells should show no signal .

• Cross-validation with multiple antibodies: Confirm results using different antibodies against S100A6 (e.g., both polyclonal and monoclonal antibodies from different manufacturers) .

• Comparison with established markers: In tissue sections, compare S100A6 staining patterns with established cell-type specific markers. For instance, in prostate tissue, S100A6 staining should match the pattern of cytokeratin 5 (a basal cell marker) but not cytokeratin 18 (a luminal cell marker) .

• mRNA correlation: Correlate protein expression detected by antibodies with mRNA expression detected by RT-PCR to ensure consistency .

How can S100A6 antibodies be utilized to study cancer progression mechanisms?

S100A6 antibodies provide valuable tools for investigating cancer progression mechanisms through several advanced applications:

• Expression profiling across cancer stages: Immunohistochemical analysis using S100A6 antibodies can map expression changes from normal tissue through premalignant lesions to invasive cancer and metastases. In prostate tissue, for example, intense S100A6 expression in basal cells of benign epithelium contrasts with complete loss in adenocarcinoma cells regardless of Gleason score and in metastatic lesions .

• Correlation with epigenetic modifications: S100A6 expression loss in certain cancer cell lines (LNCaP, LNCaP-LN3, LNCaP-Pro5) correlates with CpG methylation within the S100A6 promoter region and exon 1. Treatment with 5-Azacytidine, a DNA methyltransferase inhibitor, restores S100A6 mRNA expression, suggesting epigenetic regulation .

• Tumor microenvironment analysis: By combining S100A6 immunostaining with other markers, researchers can analyze interactions between different cell populations within the tumor microenvironment and correlate these with disease progression.

• Functional studies: Using S100A6 antibodies in combination with cell manipulation techniques (knockdown, overexpression), researchers can investigate how changes in S100A6 expression affect cancer cell behavior including proliferation, invasion, and response to therapy.

• Biomarker development: The distinctive expression pattern of S100A6 in normal versus malignant tissues makes it a potential diagnostic biomarker, particularly for prostate cancer where its loss of expression pattern is similar to other established basal cell markers (p63, 34βE12) .

What approaches can be used to study differential S100A6 expression in heterogeneous tissue samples?

Studying S100A6 expression in heterogeneous tissues requires sophisticated methodological approaches:

• Dual or multi-label immunofluorescence: Combine S100A6 antibodies with other cell type-specific markers for simultaneous detection. In prostate tissue, for example, combining S100A6 staining with cytokeratin 5 (basal cells) and cytokeratin 18 (luminal cells) helps distinguish cell populations .

• Quantitative image analysis: For precise quantification of S100A6 expression in different cell populations:

  • Maintain consistent microscope settings (aperture, detector gain, offset)

  • Capture images at optimal optical slice thickness (<0.6 μm)

  • Define regions of interest (e.g., 10 μm² areas)

  • Quantify signal intensity using appropriate software

  • Subtract background staining

  • Perform statistical analysis of the quantified data

• Laser capture microdissection: Isolate specific cell populations based on S100A6 staining patterns for subsequent molecular analysis (RT-PCR, sequencing).

• Single-cell analysis: Combine S100A6 immunostaining with single-cell RNA sequencing or mass cytometry to correlate protein expression with transcriptomic or proteomic profiles at the single-cell level.

• Spatial transcriptomics: Correlate S100A6 protein expression patterns with spatial gene expression data to understand the molecular context of expression changes in different tissue regions.

What is the significance of varied S100A6 expression patterns in corpus luteum development?

The corpus luteum (CL) demonstrates interesting S100A6 expression patterns with potential functional significance:

Immunohistochemical analysis reveals that S100A6 is expressed in corpus luteum cells but not in follicle cells . Intriguingly, different types of corpora lutea show distinct expression patterns:

• Homogeneous CL (homo CL): All luteal cells express S100A6 with relatively uniform intensity throughout the corpus luteum.

• Heterogeneous CL (hetero CL): Only a subset of luteal cells express S100A6, with varying staining intensities ranging from intense to weak within the same corpus luteum .

These distinct expression patterns may reflect:

• Different stages of corpus luteum development or regression

• Functional heterogeneity within the luteal cell population

• Varying calcium signaling requirements during luteinization

• Differential regulation of cell proliferation or apoptosis

Further research is needed to correlate these expression patterns with specific functional states and to determine if S100A6 expression could serve as a marker for corpus luteum maturation or functional capacity. Quantitative approaches measuring colocalization of S100A6 with steroidogenic enzymes like CYP11A could provide insights into the relationship between S100A6 expression and steroidogenic activity .

How should researchers interpret discrepancies between S100A6 protein and mRNA expression data?

When researchers encounter discrepancies between S100A6 protein and mRNA expression data, several factors should be considered:

• Post-transcriptional regulation: S100A6 may undergo significant post-transcriptional regulation, including:

  • microRNA-mediated repression

  • RNA stability differences

  • Translational efficiency variation

• Epigenetic regulation: In certain cell lines (e.g., LNCaP), S100A6 gene silencing occurs through CpG methylation. This can be experimentally verified, as treatment with 5-Azacytidine (a DNA methyltransferase inhibitor) restores S100A6 mRNA expression .

• Protein stability differences: Variations in S100A6 protein stability among different cell types might explain discrepancies with mRNA levels.

• Detection sensitivity thresholds: RT-PCR may detect low-level mRNA expression that doesn't translate to detectable protein. Research shows that some cell lines (LNCaP, LNCaP-LN3, LNCaP-Pro5) express very weak/absent S100A6 mRNA but completely lack detectable protein .

• Alternative splicing: Possible alternative transcripts might not be translated into functional protein or might not be detected by certain antibodies.

Recommended approach:

• Verify findings using multiple detection methods

• Confirm antibody specificity against recombinant proteins

• Test epigenetic regulation through demethylating agents

• Use quantitative PCR and Western blotting for more precise comparisons

• Consider single-cell approaches to address heterogeneity within samples

What controls should be included when using S100A6 antibodies in experimental designs?

A robust experimental design using S100A6 antibodies should include the following controls:

• Positive controls:

  • Cell lines known to express S100A6 (e.g., Du145, PC3, PC-3M, PC-3M-LN4)

  • Tissues with known S100A6 expression (e.g., basal cells in prostate epithelium)

  • Recombinant S100A6 protein (for Western blot analysis)

• Negative controls:

  • Cell lines lacking S100A6 expression (e.g., LNCaP, LNCaP-LN3, LNCaP-Pro5)

  • S100A6 knockout cell lines (e.g., S100A6 knockout HEK293T)

  • Primary antibody omission controls

  • Isotype controls

• Specificity controls:

  • Testing against related S100 family proteins (e.g., S100A11) to ensure no cross-reactivity

  • Using multiple antibodies against S100A6 (e.g., both polyclonal and monoclonal) to confirm staining patterns

  • Competing with recombinant S100A6 to block specific binding

• Loading/staining controls:

  • Housekeeping proteins (e.g., GAPDH) for Western blot normalization

  • Cell type-specific markers to validate staining patterns in tissues (e.g., cytokeratin 5 for basal cells, cytokeratin 18 for luminal cells in prostate tissue)

• Technical validation:

  • Gradient dilution series of recombinant protein for antibody sensitivity determination

  • Multiple exposure times for Western blots to ensure detection within linear range

  • Consistent microscope settings for quantitative immunofluorescence

How can researchers optimize S100A6 antibody-based detection in challenging tissue samples?

Optimizing S100A6 detection in challenging tissue samples requires attention to several methodological details:

• Fixation optimization:

  • Test multiple fixation methods if possible (formalin, paraformaldehyde, methanol)

  • Optimize fixation duration to preserve antigenicity while maintaining tissue morphology

  • For archived samples, consider extended antigen retrieval protocols

• Antigen retrieval enhancements:

  • Test both heat-induced epitope retrieval (HIER) and enzymatic methods

  • For HIER, compare different buffer systems (citrate, EDTA, Tris-EDTA at various pH)

  • Optimize retrieval duration and temperature

• Signal amplification strategies:

  • Consider tyramide signal amplification for low-abundance targets

  • Explore polymer-based detection systems for greater sensitivity

  • Use biotin-streptavidin systems with caution (check for endogenous biotin)

• Background reduction:

  • Include additional blocking steps (e.g., avidin/biotin blocking for biotin-rich tissues)

  • Test different blocking reagents (BSA, normal serum, commercial blockers)

  • Add detergents (Triton X-100, Tween-20) to reduce nonspecific binding

  • Consider autofluorescence quenching methods for fluorescent applications

• Multi-label optimization:

  • When combining S100A6 with other markers, carefully select antibodies raised in different species

  • Perform sequential staining if cross-reactivity is observed

  • Test antibody combinations on control samples before proceeding to experimental tissues

• Tissue-specific considerations:

  • For prostate tissue, be aware that S100A6 staining should be present in basal cells but absent in luminal cells

  • For ovarian tissue, note that S100A6 staining varies between different corpora lutea types

  • Consider tissue-specific autofluorescence and implement appropriate countermeasures

How might S100A6 antibodies contribute to understanding calcium signaling in cellular pathophysiology?

S100A6 antibodies can be powerful tools for investigating calcium signaling in normal and pathological states through several innovative approaches:

• Dynamic expression studies: By examining S100A6 expression under various calcium signaling conditions, researchers can determine how this calcium-binding protein responds to and potentially regulates calcium homeostasis. The protein contains two calcium-binding EF-hand domains (amino acids 12-47 and 48-83) , making it sensitive to calcium fluctuations.

• Protein interaction mapping: S100A6 interacts with multiple targets including Siah-1-interacting protein (SIP), glyceraldehydes-3-phosphate dehydrogenase (GAPDH), and various annexins . Using S100A6 antibodies in co-immunoprecipitation or proximity ligation assays can help map these interactions under different calcium concentrations.

• Subcellular localization studies: S100A6 can be found both intracellularly (where it forms homodimers and heterodimers with S100B and SGT1) and extracellularly (where it binds to RAGE receptors) . Immunofluorescence with S100A6 antibodies can track location changes in response to calcium signaling perturbations.

• Cross-pathway analysis: Combining S100A6 detection with markers of other calcium-dependent pathways can reveal integrated signaling networks and identify novel regulatory mechanisms.

• Disease model applications: Given S100A6's altered expression in various pathologies, particularly cancer, antibody-based studies can link calcium signaling abnormalities to disease progression and potentially identify new therapeutic targets.

What potential exists for using S100A6 as a diagnostic marker in conjunction with other basal cell markers?

S100A6 shows significant potential as a diagnostic marker when used in conjunction with other basal cell markers, particularly in prostate cancer diagnosis:

• Complementary marker panel: S100A6 could be integrated into diagnostic panels alongside established basal cell markers such as p63 and high molecular weight cytokeratins (34βE12). Research demonstrates that S100A6's expression pattern in prostate tissue mirrors that of cytokeratin 5, with intense staining in basal cells of benign epithelium and absence in cancer cells .

• Diagnostic accuracy enhancement: The reported loss of S100A6 expression in 100% of prostatic adenocarcinomas studied suggests that its inclusion in diagnostic panels could increase sensitivity and specificity. This is comparable to p63, which is reported to be lost in approximately 95% of prostate cancers .

• Early cancer detection: Since loss of S100A6 expression may occur at an early stage of prostate cancer development, with some high-grade prostatic intraepithelial neoplasia (HGPIN) lesions already showing absence of expression , it could potentially serve as an early diagnostic indicator.

• Atypical case resolution: In diagnostically challenging cases (atypical small acinar proliferation, pseudo-neoplastic lesions), a panel including S100A6 could provide additional evidence to support or exclude malignancy.

• Automated analysis potential: The distinct all-or-nothing staining pattern of S100A6 (intense in basal cells, absent in cancer) makes it amenable to digital pathology applications and automated image analysis algorithms.

Future validation studies should include:

• Larger cohorts with diverse cancer grades and stages

• Correlation with clinical outcomes

• Comparison with existing diagnostic approaches

• Evaluation in challenging diagnostic cases

How can quantitative analysis of S100A6 expression be standardized across different experimental platforms?

Standardizing quantitative analysis of S100A6 expression across different experimental platforms requires systematic approaches to ensure data comparability:

• Reference standards development:

  • Establish calibrated recombinant S100A6 protein standards for Western blot quantification

  • Create standardized cell lines with known S100A6 expression levels as references

  • Develop tissue microarrays with validated S100A6 expression patterns for immunohistochemistry calibration

• Standardized protocols:

  • For Western blotting: Standardize protein extraction methods, gel concentration (15-20% gradient recommended) , transfer conditions, antibody dilutions (e.g., 1 μg/mL for sheep anti-human/mouse S100A6) , and detection systems

  • For immunohistochemistry: Standardize fixation, antigen retrieval methods (heat-induced with basic pH buffers) , antibody concentration (3 μg/mL recommended for tissue sections) , incubation conditions (overnight at 4°C), and visualization systems

• Image acquisition standardization:

  • For confocal microscopy: Maintain identical settings (aperture, detector gain, offset) across experiments

  • Use optical slices of consistent thickness (<0.6 μm recommended)

  • Define standard area measurement protocols (e.g., 10 μm² areas with 180 pixels)

• Data normalization approaches:

  • Normalize Western blot data to housekeeping proteins (e.g., GAPDH)

  • For tissue analysis, use internal controls (e.g., subtract background using follicle cell intensity as control)

  • Implement statistical methods appropriate for the data type (ANOVA recommended for comparing multiple conditions)

• Reporting standards:

  • Clearly document all methodology details, including antibody source, catalog number, and dilution

  • Report quantification methods in detail

  • Present raw data alongside normalized results when possible